echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Digestive System Information > Liver Int: Oxidative stress is associated with the incidence and mortality of non-alcoholic fatty liver disease in healthy people.

    Liver Int: Oxidative stress is associated with the incidence and mortality of non-alcoholic fatty liver disease in healthy people.

    • Last Update: 2020-10-04
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Background and target non-alcoholic fatty liver disease (NAFLD) refers to the abnormal accumulation of triglycerides (TG) in liver cells without excessive alcohol consumption, and NAFLD is becoming the most common chronic liver disease in Western countries.
    NAFLD covers a wide range of diseases, from simple fat degeneration to non-alcoholic fatty hepatitis (NASH) and fibrosis.
    previous studies have shown that inflammation significantly promotes the development of NAFLD.
    During NAFLD, liver cells are no longer resistant to the toxic effects of accumulated fatty acids, leading to functional disorders of cell stability, including mitochondrial beta oxidation and endosome stress, which in turn leads to liver cell damage, which in turn leads to the secretion and cell death of inflammatory cytokines (TNF-alpha, IL-6, IL-10).
    thyl alcohol (R-SH) is involved in a variety of biological processes, such as enzyme catalysis, cell signaling and metallic complexion, and most importantly, plasma or serum thiol is considered an overall marker of systemic load in reactive species and is considered an effective antioxidant due to its high reduced activity.
    so the researchers hypothesized thatlevels of systemic oxidative stress were representative and associated with NAFLD, and studied them.
    method researchers selected 1,651 participants from a cohort study for the prevention of kidney and vascular terminal disease (PREVEND) and determined the protein-adjusted serum free -base concentration, which was diagnosed by the Fatty Liver Index (FLI-60) and the liver fat degeneration index (HSI-gt; 36).
    results of the study showed a significant decrease in protein-adjusted serum free thiol in subjects with fLI of 60.
    In the multivariate logistic regression analysis, protein-adjusted serum free thiol was associated with NAFLD (FLI-60) (concentration increased by 1x: 0.78; .95% CI 0.64-0.96), P .016).
    systolic blood pressure, diabetes, current smoking, alcohol consumption and total cholesterol are also associated with the occurrence of NAFLD (OR 0.80 (95%CI 0.65-0.99), P=.04).
    then adjusted the highly sensitive C-reactive protein, and the strated analysis showed that the reduction of serum free thiol levels was significantly correative with the onset of NAFLD and significantly related to all-cause mortality.
    quantitative analysisthe free-range data base may be an effective means of increasing the detection rate of NAFLD in the general population and reducing the total cause of mortality.
    .
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.